Immatics (IMTX) had the highest return in 2018 by a US stock in the Biotechnology Industry, returning 195,900%.
| ASSET | YEAR | % RETURN |
|---|---|---|
Immatics (IMTX) | 2018 | 195,900% |
Lunai Bioworks (LNAI) | 2018 | 98,927.41% |
XORTX Therapeutics (XRTX) | 2018 | 34,664.52% |
GT Biopharma (GTBP) | 2018 | 7,260.94% |
Lixte Biotechnology (LIXT) | 2018 | 447.06% |
Nutriband (NTRB) | 2018 | 411.98% |
ProQR Therapeutics (PRQR) | 2018 | 385.54% |
COSCIENS Biopharma (CSCI) | 2018 | 368.87% |
CareDx (CDNA) | 2018 | 240.19% |
Amarin (AMRN) | 2018 | 239.4% |
Arrowhead Pharmaceuticals (ARWR) | 2018 | 236.59% |
Vericel Corp Ord (VCEL) | 2018 | 213.51% |
Medicus Pharma Ltd Common Stock (MDCX) | 2018 | 205.73% |
Serina Therapeutics (SER) | 2018 | 164.6% |
Skye Bioscience, Inc Common Stock (SKYE) | 2018 | 163.16% |
Quantum BioPharma (QNTM) | 2018 | 145.98% |
Xenon Pharmaceuticals (XENE) | 2018 | 125.36% |
Fate Therapeutics (FATE) | 2018 | 110.33% |
Krystal Biotech (KRYS) | 2018 | 107.8% |
Kalvista Pharmaceuticals (KALV) | 2018 | 105.73% |
PTC Therapeutics (PTCT) | 2018 | 103.56% |
Sarepta Therapeutics (SRPT) | 2018 | 95.33% |
Atara Biotherapeutics (ATRA) | 2018 | 93.54% |
Veracyte (VCYT) | 2018 | 92.06% |
Zymeworks Inc Common Stock (ZYME) | 2018 | 90.9% |